Do first trimester maternal serum follistatin like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?

Basit Öğe Kaydı
dc.contributor.authorPurut, Y. E.
dc.contributor.authorBuyukbayrak, E. E.
dc.contributor.authorErcan, F.
dc.contributor.authorOrcun, A.
dc.contributor.authorMenke, M.
dc.contributor.authorKarsidag, A. Y. Karageyim
dc.date.accessioned2024-02-23T14:31:17Z
dc.date.available2024-02-23T14:31:17Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractPurpose of Investigation: The aim of this study is to evaluate whether first trimester maternal serum follistatin like 3 (FSTL3) levels can be used to predict preeclampsia and related obstetric complications. Materials and Methods: The serum levels of FSTL3, pregnancy associated plasma protein A (PAPP-A), and free beta-hCG were determined in the first trimester from a sample of 180 pregnant women. All patients had first- and second-trimester ultrasound evaluations. The pregnancy outcome was defined as 'adverse' if one of the following outcomes were observed: fetal death, preeclampsia, pregnancy-induced hypertension (PIH), delivery of a small infant for gestational age (SGA) or preterm delivery. Results: FSTL3 levels were not significantly different for preeclampsia and related adverse obstetric outcomes compared to the control group (p < 0.05). Only PAPP-A MoM values were lower in the adverse obstetric outcome group than in the control (p = 0.040). There was no significant association among FSTL3 levels and the presence of any complications, according to our ROC curve analyses (p = 0.846). Conclusions: First trimester FSTL3 levels are not predictive for preeclampsia or adverse pregnancy outcomes.en_US
dc.identifier.doi10.12891/ceog4423.2019
dc.identifier.endpage200en_US
dc.identifier.issn0390-6663
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85067023334en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage195en_US
dc.identifier.urihttps://doi.org/10.12891/ceog4423.2019
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15133
dc.identifier.volume46en_US
dc.identifier.wosWOS:000474747400004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisher7847050 Canada Incen_US
dc.relation.ispartofClinical And Experimental Obstetrics & Gynecologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdverse Outcomeen_US
dc.subjectFirst Trimesteren_US
dc.subjectFollistatin Like 3en_US
dc.subjectPreeclampsiaen_US
dc.subjectPregnancyen_US
dc.titleDo first trimester maternal serum follistatin like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu